Research Article

Alzheimer’s Amyloid-β Accelerates Cell Senescence and Suppresses the SIRT1/NRF2 Pathway in Human Microglial Cells

Yuqian An,1 Yi Li,2 Yujun Hou,3 Shichao Huang,1 and Gang Pei1,2,4,5

1State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
2School of Life Science and Technology, ShanghaiTech University, Shanghai, China
3Institute for Regenerative Medicine, Shanghai East Hospital, Shanghai Key Laboratory of Signal and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China
4Shanghai Key Laboratory of Signal and Disease Research, Collaborative Innovation Center for Brain Science, School of Life Sciences and Technology, Tongji University, Shanghai, China
5Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China

Correspondence should be addressed to Shichao Huang; huangshichao@sibcb.ac.cn and Gang Pei; gpei@sibs.ac.cn

Received 22 March 2022; Revised 11 July 2022; Accepted 18 July 2022; Published 17 August 2022

Academic Editor: Sandra Moreno

Copyright © 2022 Yuqian An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Microglia play important roles in maintenance of brain homeostasis, while due to some pathological stimuli in aging-related neurodegenerative diseases including Alzheimer’s disease, they are malfunctioning. Here, we demonstrated that amyloid-β (Aβ) accelerated cell senescence characterized by the upregulation of p21 and PAI-1 as well as senescence-associated beta-galactosidase (SA-β-gal) in human microglial cells. Consistently, Aβ induced the senescence-associated mitochondrial dysfunctions such as repression of ATP production, oxygen consumption rate (OCR), and mitochondrial membrane potential and enhancement of ROS production. Furthermore, Aβ was found to significantly suppress mRNA expression and protein level of Sirtuin-1 (SIRT1), a key regulator of senescence, and inhibit mRNA expression and translocation of NRF2, a critical transcription factor in inflammatory responses, leading to impairment of phagocytosis. Rescue of SIRT1, as expected, could counteract the pathological effects of Aβ. In summary, our findings revealed that Aβ accelerates human microglial senescence mainly through its suppression of the SIRT1/NRF2 pathway and suggested that genetic and pharmaceutical rescue of SIRT1 may provide a potential alternative treatment.

1. Introduction

Alzheimer’s disease (AD) is an age-related neurodegenerative disease and is often characterized by tau aggregation and amyloid-β (Aβ) deposition [1, 2]. It is identified that accumulation and aggregation of Aβ drives subsequent pathological events such as neuroinflammation, mitochondrial dysfunction, and cell senescence [3–5]. Microglia are the brain’s innate immune cells and play important roles in AD [6, 7]. Compelling evidence suggests that microglia, in the aged neurodegenerative brain, are activated and recruited to Aβ plaques and secreted proinflammatory cytokines such as IL-1β, IL-6, and TNF-α, which are similar to immunosenesence of macrophages [8]. Cell senescence affects phagocytosis of microglial in AD mice [9]. Cell senescence also leads to microglia dysfunction, resulting in inaccurate response to external stimuli and neurodegeneration worsening [8, 10, 11]. The prominent feature of microglial senescence includes the morphological alteration described as “dystrophy,” [12] telomere shortening [13, 14], and functional alterations [8]. During senescence, microglia shift the glycolytic metabolic state featured by the mitochondrial activity [3, 15], change their inflammatory profile, increase the immunophenotypic expression, and more importantly, switch from neuroprotective to neurotoxic role when activated [10, 16–18]. Aβ, the main contributor of AD, has been
suggested to accelerated microglial senescence [13]. However, there is still no direct evidence so far showing the influence of Aβ deposition on human microglial senescence.

Sirtuin-1 (SIRT1) is a NAD-dependent deacetylase that participates in the regulation of cell senescence, metabolism, inflammation, and mitochondrial function [19, 20]. Under homeostasis, the expression and activity of SIRT1 is controlled by multiple mechanisms and maintained at normal state [21, 22]. However, during aging, metabolic disorder, or neurodegenerative diseases, the expression of SIRT1 is diminished, intensifying oxidative stress potentially [23–25]. It is well known that sharp decrease of SIRT1 level is closely related to the accumulation of Aβ and tau proteins in AD patients [26–28]. SIRT1 has been suggested to reduce Aβ deposition and toxicity and improved AD pathology based on several earlier in vitro and in vivo studies [29–31]. Furthermore, SIRT1 is closely associated with nuclear factor E2-related factor 2 (NRF2), a transcription factor involved in regulating inflammatory responses through activating its downstream genes [32–34]. Therefore, regulation of the SIRT1/NRF2 pathway may provide a hopeful way for preventing or treating aging-related neurodegenerative disease.

Here, we used Aβ to induce cellular senescence in human microglial cells. After Aβ stimulation, we found the senescence-related mitochondrial functions were exacerbated significantly. We also detected that Aβ induction affected phagocytosis and ROS production of microglia and downregulated the SIRT1/NRF2 pathway. Overexpression of SIRT1 or using SIRT1 activator such as aspirin can counteract Aβ-induced cellular senescence. In summary, our results suggest that the SIRT1/NRF2 pathway is a therapeutic target for AD-related cellular senescence.

2. Materials and Methods

2.1. Cell Culture. Human microglial cells HMC3 were obtained from ATCC (#CRL0314). Cells were cultured in MEM with 10% FBS and 1% penicillin-streptomycin in a humidified incubator with 5% CO₂/95% air at 37°C.

2.2. Aβ Peptide Preparation. The Aβ peptides (Chinese peptide) were prepared according to the protocols described previously [34, 35]. In brief, Aβ peptides were dissolved in HFIP (Sigma, #105228) to a final concentration of 1 mM, the HFIP-treated Aβ peptides were resolved in DMSO and then diluted to a concentration of 100 µM with DMEM/F12 phenol-red free medium and incubated at 4°C for 24 h. After centrifugation at 12,000 g for 10 min, the supernatant with soluble Aβ was added to cultures. Aβ1-42 peptides (Beyotime, #P9005) were used as a negative control. Aβ1-42 peptides were prepared using the same protocol. The concentration of Aβ1-42 was 10 µM. In this paper, Aβ presented Aβ1-42.

2.3. SA-β-Gal Staining. Senescence-associated β-galactosidase (SA-β-gal) activity was performed using the SA-β-gal staining kit (Beyotime, #C0602), according to the manufacturer’s instructions. In brief, cells were plated in the density of 40,000 cells per well into a 24-well plate. After 24 h seeding, cells were treated with Aβ for 72 h, then the cells were fixed with 4% formaldehyde in PBS for 15 min, and the fixed cells were stained with SA-β-Gal staining solution at 37°C for 15 h. The percentage of positively stained cells were calculated based on three replicates.

2.4. Reverse Transcription and Quantitative Real-Time PCR. HMC3 cells were stimulated with Aβ for 72 h; then, the cells were extracted by TRI Reagent (Sigma, #T9424) to obtain total RNA according to the manufacturer’s instructions. cDNA was synthesized using cDNA Synthesis kit (TaKaRa, #RR036B) and qPCR analysis was done with power SYBRGreen PCR master mix (Vazyme, #Q712). Primers used were as follows: PAI-1 (forward: 5'-ACCGCAACGTTGTTTCTCTA-3' and reverse: 5'-TTGAATCCCATAGCTGGTGAAT-3'), p21 (forward: 5'-CGAAGTCGTTCCCAGGG-3' and reverse: 5'-AGTCGTTGGCTTTGGAGGAGGAGAT-3'), CCNA1 (forward: 5'-GAATTTGTGCCTGTCCTGAGTG-3' and reverse: 5'-TCTGATATGGAGGAGTGAAGTTCTGAGG-3'), CCND1 (forward: 5'-ATGTTCTGGCCTCCTCTAGATATGA-3' and reverse: 5'-CAGTTCTCTCAAGGTGG-3'), SIRT5 (forward: 5'-GCCATAAGGCTGGAGTGACCGGCG-3' and reverse: 5'-CAGTTCTCTCAAGGTGG-3'), NFR2 (forward: 5'-TCACGCGAGGAAAGGATGATG-3' and reverse: 5'-CCACTGTTGCTGACGTGGTGTCTTTGGGAGGAGGAT-3'), TNFa (forward: 5'-CCTCCTCTCTCTATACGGCCCTG-3' and reverse: 5'-AGACGTCTCGGGATGATGAGGAGGATGATGAGGAGGATG-3'), ILLbeta (forward: 5'-ATGATGCTTATACAGTGAGGAGGAGGATGATGAGGAGGATG-3' and reverse: 5'-TGCCGAGGTACGTGGTGTCTTTGGGAGGAGGATGATGAGGAGGATG-3'), IL6 (forward: 5'-ACTACACTCTTCCAGAAGGATTGGTGAGGAGGAGGATGATGAGGAGGATG-3' and reverse: 5'-CTGAGGTGTGAGGAGGAGGATGATGAGGAGGATG-3'). The reaction parameters were as follows: 95°C for 10 min; 95°C for 30 s, 40 cycle; 60°C for 30 s; and 72°C for 30 s. An additional cycle was performed for evaluation of primer’s dissociation curve: 95°C for 1 min, 95°C for 30 s, 40 cycle; 60°C for 30 s. The gene levels were to be measured by using the 2-ΔΔCT method.

2.5. Western Blotting. Western blotting was performed as described previously [34]. Briefly, 20 µg samples were loaded and separated on 10% or 12% SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% milk in TBST for 1 h, we used TBST to dilute primary and secondary antibodies. Membranes were incubated with primary antibody overnight at 4°C, washed in TBST, and incubated with HRP-conjugated secondary antibody for 60 min. The proteins of interest were performed using an ECL western blot detection kit (Bio-Rad). ImageJ software was used to evaluate the densitometry. Actin or proliferating cell nuclear antigen (PCNA) was used as loading control. Antibodies were used as follows: p53 (Beyotime, #AF7671), PAI-1 (Cell
2.10. Nuclear and Cytoplasmic Extraction. HMC3 cells were cultured in 6 cm plates, grew for 24 h, and then were treated with Aβ for indicated time. Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, #P0028) was used in this experiment according to the manufacturer’s instructions. In brief, 80 μl Buffer A was added to cells for 10 min, next 5 μl Buffer B was added, then the cells were centrifugated at 12,000 g for 5 min, and the supernatant was the cytoplasmic protein. The precipitation was resolved with 25 μl Buffer C for 30 min and centrifuged at 16,000 g for 10 min at 4°C to obtain the nuclear fraction.

2.11. SIRT1 Overexpression. SIRT1 cDNA was made from pCMV-SIRT1-t1-Flag (purchased from Sino Biological) via PCR amplification. SIRT1 cDNA was cloned into the FUGW vector using Seamless Cloning Kit (Beyotime, D7010M) and confirmed by DNA sequencing. HMC3 cells were plated into 24-well or 6 cm dish at appropriate intensity and cultured overnight. We transfected 150 ng plasmid per well into 24-well or 1.5 μg plasmid per well into 6 cm dish. SIRT1 plasmid or FUGW plasmid was transfected using ViaFect reagent (Promega, #E4981) according to manufacturer’s instructions. After transfection for 24 h, cells were stimulated by Aβ for 72 h. The knockdown of SIRT1 was performed by the transfection with specific siRNA (Tsingke Biotechnology Co., Ltd.) via ViaFect reagent. The cloning primers used were as follows: SIRT1 (forward: 5’-TGGGCTGAGGTCGACCTGAATGTCGATGGAAGCAGCTTC-3’ and reverse: 5’-TTGATATCGGAATCTGACTATGATGATTTGTTCGATTGAGTTGATGCTT-3’). The siRNA primers were as follows: siSIRT1-1 (forward: 5’-CACCUGAUGGAUGUAUAUATT-3’ and reverse: 5’-AUCAAUCCACUCAGGUGTTT-3’). siSIRT1-2 (forward: 5’-GUCCUGUAUGUAUAUATT-3’ and reverse: 5’-AUACUGACAGACTT-3’).

3. Results

3.1. Aβ Induced Senescence Gene Activation in Human Microglial Cells. Several studies have shown strong evidences that cellular senescence increased significantly in AD mice [33, 35, 36]. Here, we treated human microglial cells HMC3 with 10 μM Aβ for different times and evaluated the gene expression of senescence. Compared with the Aβ42-1 treatment control group, cells treated with Aβ displayed significantly higher expression of senescence-associated genes (Figures 1(a)-1(d)). Similarly, the protein level of p53, PAI-1, and p21 was detected, showing that PAI-1 and p21 was markedly increased at 72 h with 10 μM Aβ stimulation, but there was no obvious change about the level of p53 (Figures 1(e)-1(h)). Thus, treatment of Aβ for 72 h was applied for the subsequent experiments. We also
Figure 1: Continued.
Con (µM) Ctrl 1 3 10 10 kDa

(i)

(ii)

(iii)

(iv)

(v)

Figure 1: Continued.
measured the effects of different Aβ concentrations and found that Aβ increased the protein level of PAI-1 and p21 significantly at 10 μM (Figures 1(i)–1(l)). Furthermore, we performed a senescence-associated beta-galactosidase (SA-β-gal) assay to confirm the senescence phenotype of HMC3 cells. As shown in Figures 1(m) and 1(n), an increased percentage of SA-β-gal-positive cells is observed in cell culture treated with 10 μM Aβ. We also evaluated SASP markers such as TNF-α, IL-1β, and IL-6 by qPCR (Figures 1(o)–1(q)). These results indicated that Aβ induced senescence in human microglial cells.

3.2. Aβ Accelerated Mitochondrial Dysfunction in Microglia. Recent studies revealed that cellular senescence is associated with mitochondrial defects [37–39]. We therefore assessed the effects of Aβ on mitochondrial functions in HMC3 cells. To evaluate mitochondrial functions, we tested the oxygen consumption rate (OCR) in HMC3 after treatment with oligomycin (ATP synthase inhibitor), FCCP (H+ ionophore), or rotenone and antimycin A (electron-transport chain inhibitor). These results revealed that Aβ treatment significantly diminished the maximal respiratory capacity of mitochondria and ATP production in microglia compared with vehicle. Aβ treatment also reduced basal respiration and spare capacity OCR, but no statistically significant change was observed (Figures 2(a)–2(c)). Aβ42–1, as the negative control, had no obvious effect. Furthermore, we tested whether Aβ could induce the loss of mitochondrial membrane potential (MMP). In this study, we used JC-1 probe to evaluate MMP in HMC3 cells. Red fluorescence and green fluorescence characterized high and low mitochondrial membrane permeability, respectively, and the ratio could signify the change of MMP. Cells treated with Aβ increased green fluorescence intensity (Figure 2(f)) and reduced the red/green fluorescence (Figure 2(g)), indicating Aβ induced depolarization. Taken together, our data indicated that Aβ induced mitochondrial dysfunctions through reduction of OCR and MMP.

3.3. Aβ Decreased Microglial Phagocytosis and Increased ROS Production. Phagocytosis, one of the most important features of microglia, has been reported to be decreased significantly in AD mice [3, 40–42]. Moreover, recent studies showed that the phagocytic activity of mouse primary microglial cells was markedly decreased with Aβ stimulation, which is associated with mitochondrial dysfunction concluding reduction of OCR [3, 42]. However, whether Aβ could affect phagocytosis in human microglial cells is unknown. Here, we treated HMC3 cells with Aβ for 72 h and mixed with fluorescent latex beads for 3 h. The phagocytic capacity was assessed by confocal microscope (Figures 3(a)–3(c)). And also, the average cell fluorescence intensity was detected at 485 nm excitation/538 nm emission using the a BioTek fluorescence reader (Figure 3(d)). Aβ also decreased human microglial phagocytosis by flow cytometry (Supplementary Figure 1A). The results revealed Aβ significantly reduced phagocytic capacity (Figures 3(a)–3(d)). Inflammatory responses, another vital feature of microglia, increase dramatically in AD mice and AD patients. Aβ could
Figure 2: Aβ accelerated microglial mitochondrial dysfunctions. (a–e) Aβ-induced reduction of oxygen consumption rate (OCR) in HMC3 cells. Seahorse assays showed mitochondrial bioenergetics in HMC3 cells with 10 μM Aβ for 72 h. (a) The representative graph of the mitochondrial stress test detailing the four key parameters of mitochondrial function through sequential addition of oligomycin (1 μM), FCCP (1 μM), and rotenone/antimycin A (1 μM each), which allowed the measurement of basal respiration (b), the maximal respiration (c), the spare respiratory capacity (d), and mitochondrial ATP production (e). (f, g) HMC3 cells were treated with 10 μM Aβ for 72 h. The cells were stained with JC-1 dye and then captured by Zeiss 880 microscope (f), and the fluorescence intensity in (f) was quantified using BioTek reader (g). Scale bars, 100 μm. The data are presented as mean ± SEM, n ≥ 3 independent experiments, **p < 0.01 and **** p < 0.0001, analyzed by one-way ANOVA followed by Bonferroni’s test.
Figure 3: Aβ decreased microglial phagocytosis and increased ROS production. (a–d) HMC3 cells were mixed with the fluorescent latex beads. The cells were captured by Zeiss 880 microscope (a). Scale bars, 100 μm. (b, c) The quantification of in (a). The fluorescence intensity was also quantified using BioTek reader (d). (e, f) ROS production in HMC3 cells was investigated with the DCFH-DA probe. The pictures were obtained by Zeiss microscope. Scale bars, 100 μm. The fluorescence intensity in (e) was quantified using BioTek reader (f). The data are presented as mean ± SEM, n ≥ 3 independent experiments; **p < 0.01, ***p < 0.001, and ****p < 0.0001, analyzed by one-way ANOVA followed by Bonferroni’s test.
Figure 4: Aβ downregulated the SIRT1/NRF2 pathway in the cells. (a–i) HMC3 microglia cells were treated with 10 μM Aβ for different times. (a, b) mRNA expression of SIRT1 and SIRT5. (c) Protein level of SIRT1 and SIRT5 was detected by western blotting. (d, e) The quantification of relative protein levels in (c). (f) mRNA expression of Nrf2. (g) Protein levels of N-Nrf2 and C-Nrf2 were observed by western blotting. (h, i) The quantification of relative protein levels in (g). The data are presented as mean ± SEM, n ≥ 3 independent experiments; *p < 0.05 and **p < 0.01, analyzed by one-way ANOVA followed by Bonferroni’s test.
\( \text{SIRT1} \) 

PAI-1 

\( \text{p21} \) 

\( \text{Actin} \) 

(a)

(b)

(c)

(d)

(e)

\( \text{SA-\( \beta \)-gal} \) 

\( \text{N-Nrf2} \) 

\( \text{PCNA} \) 

\( \text{C-Nrf2} \) 

\( \text{Actin} \) 

**Figure 5: Continued.**
induce ROS generation, thus causing oxidative stress of microglia. Here, we stimulated human microglial cells with Aβ for 72 h and assessed the intracellular ROS level by staining with the DCFH-DA probe. The probe has no fluorescence and can pass through plasma membrane freely and produce fluorescent DCF when oxidized by ROS. Results showed that treatment with Aβ markedly increased DCF fluorescence (Figures 3(e) and 3(f)). Taken together, these results indicated Aβ significantly impaired phagocytic capacity and increased ROS production in human microglia cells.

3.4. Aβ Downregulated the SIRT1/NRF2 Pathway in the Cells. SIRT1, which is a NAD+-dependent deacetylase, has been reported to play an important role in age-related neurodegenerative diseases [19, 43, 44]. Recent studies have shown that the expression of SIRT1 was decreased markedly in AD patients [26–28]. Here, we wanted to understand whether SIRT1 took part in Aβ-induced microglial senescence. We treated cells with Aβ for different times and found that at 72 h, Aβ reduced the mRNA expression of SIRT1 and downregulated the protein level of SIRT1 (Figures 4(a)–4(e)). SIRT5, another SIRT family protein, was not affected after Aβ stimulation. Furthermore, accumulating evidence showed that SIRT1 is involved in the activation of nuclear factor E2-related factor 2 (NRF2) [32, 33]. NRF2 can be served as a sensor of oxidative stress. Next, we investigated whether Aβ treatment affected nuclear translocation of NRF2. The results indicated that Aβ reduced the mRNA expression of NRF2 (Figure 4(f)).
Aspirin ($\mu$M) 0 0 10 30 100

(a) SIRT1/Actin (Fold of ctrl)

Aspirin ($\mu$M) 0 0 10 30 100

(b) PAI-1/Actin (Fold of ctrl)

Aspirin ($\mu$M) 0 0 10 30 100

(c) p21/Actin (Fold of ctrl)

Aspirin ($\mu$M) 0 0 100

(d) Aβ

SA-β-gal (%)

(e) JC-1 red/green ratio (Fold of ctrl)

(f) ROS production (Fold of ctrl)

Figure 6: Continued.
Moreover, Aβ inhibited NRF2 nuclear translocation (N-Nrf2) in a time-dependent manner (Figures 4(g) and 4(h)), NRF2 levels in the cytoplasm (C-Nrf2) were not statistically changed (Figures 4(g) and 4(i)). In conclusion, the downregulated SIRT1/NRF2 pathway accelerated cellular senescence in human microglia. Transfected of HMC3 cells with siSIRT1-1 or siSIRT1-2 downregulated protein level of SIRT1 detected by western blotting. (b) The quantification of the percentage of SA-β-gal cells. Scar bar, 50 μm. (e) The cells were stained with JC-1 dye and the fluorescence intensity was quantified using BioTek reader. (f) HMC3 cells were incubated with DCFH-DA and Hoechst; then, the fluorescence intensity was detected by BioTek reader. (g) The fluorescent latex beads were added to the medium and incubated at 37°C for 3 h. The fluorescence intensity was quantified using BioTek reader. The data are presented as mean ± SEM, n ≥ 3 independent experiments; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, analyzed by one-way ANOVA followed by Bonferroni’s test.

3.5. Overexpression of SIRT1 Rescues Aβ-Induced Senescence and Mitochondrial Dysfunctions. Since the protein level of SIRT1 has been reduced with Aβ treatment, we next tested whether overexpression of SIRT1 could rescue Aβ defects including senescence, mitochondrial disability, and microglial dysfunctions. Here, we transfected HMC3 cells with SIRT1 plasmid or FUGW plasmid. As shown in Figures 5(a) and 5(b), Aβ markedly downregulated SIRT1 expression and upregulated senescence genes including PAI-1 and p21, but SIRT1 overexpression almost counteracted the influence of Aβ-induced senescence in HMC3 cells (Figures 5(a) and 5(b)). Furthermore, SIRT1 overexpression decreased the SA-β-gal signal in the cells relative to the vehicle controls (Figures 5(c) and 5(d)). We next examined whether overexpression of SIRT1 could promote NR2F nuclear translocation. Cells transfected with SIRT1 translocated NR2F to the nucleus (Figures 5(e) and 5(f)). Interestingly, overexpression of SIRT1 prevented Aβ impaired mitochondrial membrane potential (Figure 5(g) and Supplementary Figure 3A). Similarly, Aβ-induced ROS production was significantly rescued by SIRT1 overexpression (Figure 5(h) and Supplementary Figure 3B). Moreover, SIRT1 treatment involved in the enhancement of Aβ phagocytosis (Figure 5(i) and and Supplementary Figure 3C). Together, these data suggested that SIRT1 protein was dispensable for the Aβ-mediated cell senescence, mitochondrial dysfunctions, and microglial state.

3.6. Aspirin Alleviates Aβ-Induced Senescence and Mitochondrial Dysfunctions via Upregulation of SIRT1 Pathway. In this paper, we wanted to find some drugs which could relieve microglial cellular senescence. Surprisingly, treatment of aspirin in HMC3 was found to rescue cellular senescence after Aβ stimulation (Figures 6(a) and 6(b)). Aspirin is a common drug, which was widely used for treating pain, fever, inflammation, and cardiovascular diseases [45–47]. Previous studies showed that aspirin could activate SIRT1 in liver cells and in endothelial cells [48, 49]. Here, pretreatment with aspirin for 4 h did lower senescence-associated protein levels obviously (Figures 6(a) and 6(b)). Meanwhile, 100 μM aspirin markedly increased SIRT1 level. To assess the effect of aspirin on senescent microglia cells, SA-β-gal activity was detected and there was a significant reduction in the number of SA-β-gal-positive cells in aspirin-treated cells (Figures 6(c) and 6(d)). We also investigated whether aspirin could affect mitochondrial functions and found that aspirin increased mitochondrial membrane potential using JC-1 probe (Figure 6(e) and Supplementary Figure 4A). Lastly, 100 μM aspirin significantly inhibited ROS production (Figure 6(f) and Supplementary Figure 4B) and increased phagocytic capacity in HMC3 cells (Figure 6(g) and Supplementary Figure 4C). In summary, aspirin may be a potential drug in aging-related neurodegenerative diseases through the SIRT1 pathway.

4. Discussion

AD is a neurodegenerative disease mainly characterized by the progressive aggregation of Aβ [50, 51]. The microglia play an important role in the maintenance of brain homeostasis [52, 53]. Recent studies indicated that microglia can be...
categorized into two opposite types: toxic phenotype and protective phenotype [54, 55]. Toxic microglia produce chemokines and cytokines such as CCL2, IL-1β, IL-6, IL-12, and TNF-α and generate nitrogen species and reactive oxygen. However, protective microglia produce anti-inflammatory cytokines such as IL-10 and TGF-β and growth factors. The dynamic changes of toxic/protective phenotypes are critically associated with AD. Endogenous stimuli including Aβ and tau may persistently activate pro-inflammatory responses and finally aggravate progression of neurodegenerative disease [35]. The expression of proinflammatory cytokines is one of the hallmarks of cellular senescence [37]. In the present study, we demonstrate that Aβ could induce microglial senescence. Srinivasan et al. revealed Alzheimer’s patient microglia exhibited enhanced aging [56]. We also find that Aβ aggravate senescence-associated mitochondrial dysfunctions and impair microglial functions. Interestingly, we revealed that the SIRT1/NRF2 pathway is partly reduced by Aβ stimulation. Notably, overexpression of SIRT1 or use SIRT1 activator such as aspirin may rescue Aβ defects.

Increasing evidences point out that mitochondrial dysfunction is one of the hallmarks of aging [57, 58], attributing to the accumulation of mtDNA mutations, damaged fission and fusion behavior, weakened membrane potential, abnormal metabolism, and defective electron transport chain (ETC) function in mitochondrial. Mitochondrial dysfunctions in microglia has been linked to the development of aging-related neurodegenerative diseases such as AD [59–61]. The high level of reactive oxygen species (ROS) and loss of mitochondrial membrane potential have been observed in human microglial cells with Aβ stimulation in our work. Previous studies reported that a metabolic switch from mitochondrial OXPHOS to anaerobic glycolysis in Aβ-treated primary mouse microglia is associated with microglia phagocytosis [3, 42]. Here, we detected Aβ treatment significantly reduced OCR levels in human microglia cells and impaired the capacity of microglia phagocytosis. Thus, therapies targeting basic mitochondrial processes hold great promise.

Sirtuins are class III histone deacylases possessing outstanding properties in preventing diseases and reversing some aspects of aging [62–64]. SIRT1 has been shown to regulate cellular metabolism by acting as a cellular sensor [65]. Increasing studies indicate that the expression of SIRT1 is significantly diminished in aging, metabolic, and neurodegenerative diseases, leading to oxidative stress [66]. Importantly, the protein level of SIRT1 is also decreased dramatically in AD mice brains and AD patients, which is closely related to the accumulation of Aβ and tau proteins than in normal aging individuals [26, 67]. Here, we found SIRT1 was decreased after Aβ stimulation in human microglia cells. At the same time, SIRT1-associated NRF2 nuclear translocation was also reduced after Aβ treatment. Aspirin is one of the most widely used treatments for cardiovascular disease. Aspirin has obviously anti-inflammatory function. We found that aspirin could increase SIRT1 production and alleviate human microglial senescence. Aspirin has been reported to reduce amyloid plaque in a mouse model of AD [68]. However, aspirin does not reduce the risk of Alzheimer’s disease in clinical trial [69]. There are many differences between cell lines and human. Therefore, activating the SIRT1/NRF2 pathway may provide a promising way for prevention and treatment of aging-related neurodegenerative diseases.

**Data Availability**

The data, methods, and study materials used to conduct the research will be available from the corresponding authors on reasonable request.

**Conflicts of Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Authors’ Contributions**

Gang Pei conceived and designed the experiments. Yuqian An performed the experiments. Yi Li generated plasmids. Gang Pei and Yujun Hou checked and revised it. All authors approved to submit this version to this publication.

**Acknowledgments**

This study was supported by the National Key Research and Development Program of China (2018YFA0108003), the “Strategic Priority Research Program” of the Chinese Academy of Sciences (XDA16010309), and the National Science Foundation for Young Scientists of China (81901094).

**Supplementary Materials**

Figure 1: Aβ decreased human microglial phagocytosis by flow cytometry. (A) Human microglia cells were mixed with the fluorescent latex beads. The cells were detected by flow cytometry. Aβ42-43 as a negative ctrl. Figure 2: knockdown SIRT1 accelerated cellular senescence in human microglial cells. (A, B) HMC3 cells were transfected with negative control (ctrl), siSIRT1-1, and siSIRT1-2 for 72 h. (A) SIRT1 protein level was detected by western blot. (B) Quantification of SIRT1 protein level in (A). (C) The representative images of SA-β-gal staining in HMC3 cells transfected with siSIRT1 stained after 72 h. (D) Quantification of SA-β-gal-positive cells in (C). Scale bars, 100 μm. The data are presented as mean ± SEM, n ≥ 3 independent experiments, **p < 0.01 and ****p < 0.0001, analyzed by one-way ANOVA followed by Bonferroni’s test. Figure 3. Overexpression of SIRT1 rescues Aβ-induced mitochondrial dysfunction, ROS production, and phagocytic capacity. (A–C) HMC3 cells were transfected with SIRT1 plasmid (150 ng) or FuGW (150 ng) followed by Aβ treatment for 72 h. (A) JC-1 dye was used to detect mitochondrial membrane potential and then captured by Zeiss 880 microscope. Scale bars, 100 μm. (B) HMC3 cells were stained with DCFH-DA probe to detect ROS production by Zeiss microscope. Scale bars, 100 μm. (C) HMC3 cells were mixed with the
fluorescent latex beads to detect phagocytic capacity. The cells were captured by Zeiss 880 microscope. Scale bars, 100 μm. Figure 4. Aspirin alleviates Aβ-induced mitochondrial dysfunction, ROS production and phagocytic capacity. (A) HMC3 cells were stained with JC-1 dye and then captured by Zeiss 880 microscope. Scale bars, 100 μm. (B) HMC3 cells were stained with DCFH-DA probe to detect ROS production by Zeiss microscope. Scale bars, 100 μm. (C) HMC3 cells were mixed with the fluorescent latex beads. The cells were captured by Zeiss 880 microscope. Scale bars, 100 μm. (Supplementary Materials)

References

[1] J. A. Hardy and G. A. Higgins, "Alzheimer’s disease: the amyloid cascade hypothesis," Science, vol. 256, no. 5054, pp. 184-185, 1992.
[2] S. Gandy, "The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease," The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1121–1129, 2005.
[3] S. H. Baik, S. Kang, W. Lee et al., "A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer’s disease," Cell Metabolism, vol. 30, pp. 493–507, 2019.
[4] A. U. Joshi, P. S. Minhas, S. A. Liddelow et al., "Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration," Nature Neuroscience, vol. 22, no. 10, pp. 1635–1648, 2019.
[5] D. J. Baker and R. C. Petersen, "Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives," The Journal of Clinical Investigation, vol. 128, no. 4, pp. 1208–1216, 2018.
[6] W. F. Hickey and H. Kimura, "Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo," Science, vol. 239, no. 4837, pp. 290–292, 1988.
[7] F. Ginhoux, S. Lim, G. Hoeffel, D. Low, and T. Huber, "Origin and differentiation of microglia," Frontiers in Cellular Neuroscience, vol. 7, p. 45, 2013.
[8] X. G. Luo, J. Q. Ding, and S. D. Chen, "Microglia in the aging brain: relevance to neurodegeneration," Molecular Neurodegeneration, vol. 5, no. 1, pp. 1–9, 2010.
[9] J. H. Brellstaff, M. Mason, T. Katsinelos et al., "Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates," Science Advances, vol. 7, no. 43, article eabg9880, 2021.
[10] M. Sawada, H. Sawada, and T. Nagatsu, "Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases," Neurodegenerative Diseases, vol. 5, no. 3-4, pp. 254–256, 2008.
[11] Y. Li, J. Lu, Y. Hou, S. Huang, and G. Pei, "Alzheimer’s amyloid-β accelerates human neuronal cell senescence which could be rescued by Sir2uin-1 and aspirin," Frontiers in Cellular Neuroscience, vol. 16, article 906270, 2022.
[12] W. J. Streit, N. W. Sammons, A. J. Kuhns, and D. L. Sparks, "Dystrophic microglia in the aging human brain," Glia, vol. 45, no. 2, pp. 208–212, 2004.
[13] B. E. Flanary, N. W. Sammons, C. Nguyen, D. Walker, and W. J. Streit, "Evidence that aging and amyloid promote microglial cell senescence," Rejuvenation Research, vol. 10, no. 1, pp. 61–74, 2007.
[14] B. E. Flanary and W. J. Streit, "Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes," Glia, vol. 45, no. 1, pp. 75–88, 2004.
[15] L. H. Fairley, J. H. Wong, and A. M. Barron, "Mitochondrial regulation of microglial Immunometabolism in Alzheimer’s disease," Frontiers in Immunology, vol. 12, article 624538, 2021.
[16] S. M. Ye and R. W. Johnson, "An age-related decline in interleukin-10 may contribute to the increased expression of interleukin-6 in brain of aged mice," Neuroimmunomodulation, vol. 9, pp. 183–192, 2002.
[17] A. Sierra, A. C. Gottfried-Blackmore, B. S. McEwen, and K. Bulloch, "Microglia derived from aging mice exhibit an altered inflammatory profile," Glia, vol. 55, no. 4, pp. 412–424, 2007.
[18] L. G. Sheffield and N. E. Berman, "Microglial expression of MHC class II increases in normal aging of nonhuman primates," Neurobiology of Aging, vol. 19, no. 1, pp. 47–55, 1998.
[19] A. Z. Herskovits and L. Guarente, "SIRT1 in neurodevelopment and brain senescence," Neuron, vol. 81, no. 3, pp. 471–483, 2014.
[20] C. Y. Xu, L. Wang, P. Fozoumi et al., "SIRT1 is downregulated by autophagy in senescence and ageing," Nature Cell Biology, vol. 22, no. 10, pp. 1170–1179, 2020.
[21] F. Imperatore, J. Maurizio, S. Vargas Aguilar et al., "SIRT1 regulates macrophage self-renewal," The EMBO Journal, vol. 36, no. 16, pp. 2353–2372, 2017.
[22] Z. Radak, K. Suzuki, A. Posa, Z. Petrovsky, E. Koltai, and I. Boldogh, "The systemic role of SIRT1 in exercise mediated adaptation," Redox Biology, vol. 35, article 101467, 2020.
[23] Y. Fang, X. Wang, D. Yang et al., "Relieving cellular energy stress in aging, neurodegenerative, and metabolic diseases, SIRT1 as a therapeutic and promising node," Frontiers in Aging Neuroscience, vol. 13, article 738686, 2021.
[24] P. Mishra, A. K. Mittal, H. Kalonia et al., "SIRT1 promotes neuronal fortification in neurodegenerative diseases through attenuation of pathological hallmarks and enhancement of cellular lifespan," Current Neuropharmacology, vol. 19, no. 7, pp. 1019–1037, 2021.
[25] F. Jiao and Z. Gong, "The beneficial roles of SIRT1 in neuroinflammation-related diseases," Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 6782872, 19 pages, 2020.
[26] K. Cao, Y. T. Dong, J. Xiang et al., "Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer’s disease,” Journal of Clinical Pathology, vol. 71, no. 12, pp. 1090–1099, 2018.
[27] Y. Hou, H. Chen, Q. He et al., "Changes in methylation patterns of multiple genes from peripheral blood leucocytes of Alzheimer’s disease patients," Acta Neuropsychiatric, vol. 25, no. 2, pp. 66–76, 2013.
[28] C. Julien, C. Tremblay, É. Émond et al., "Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease," Journal of Neuropathology and Experimental Neurology, vol. 68, no. 1, pp. 48–58, 2009.
[29] A. Conte, S. Pellegrini, and D. Tagliazucchi, "Synergistic protection of PC12 cells from β-amyloid toxicity by resveratrol and catechin," Brain Research Bulletin, vol. 62, no. 1, pp. 29–38, 2003.
16 Oxidative Medicine and Cellular Longevity

[30] J. Chen, Y. Zhou, S. Mueller-Steiner et al., “SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling,” *The Journal of Biological Chemistry*, vol. 280, no. 48, pp. 40364–40374, 2005.

[31] W. Qin, T. Yang, L. Ho et al., “Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction,” *The Journal of Biological Chemistry*, vol. 281, no. 31, pp. 21745–21754, 2006.

[32] B. I. Ario, B. Tastan, E. Tarakcioglu et al., “Melatonin attenuates LPS-induced acute depressive-like behaviors and microglial NLRP3 inflammasome activation through the SIRT1/Nrf2 pathway,” *Frontiers in Immunology*, vol. 10, p. 1511, 2019.

[33] X. S. Zhang, Y. Lu, W. Li et al., “Astaxanthin ameliorates oxidative stress and neuronal apoptosis via SIRT1/NRF2/Prx2/ASK1/p38 after traumatic brain injury in mice,” *British Journal of Pharmacology*, vol. 178, no. 5, pp. 1114–1132, 2021.

[34] Y. An, H. Zhang, S. Huang, and G. Pei, “PL201, a reported rhamnoside against Alzheimer’s disease pathology, alleviates neuroinflammation and stimulates Nrf2 signaling,” *Frontiers in Immunology*, vol. 11, p. 162, 2020.

[35] Y. Hou, Y. Wei, S. Lautrup et al., “NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS-STING,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 118, no. 37, 2021.

[36] P. Zhang, Y. Kishimoto, I. Grammatikakis et al., “Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model,” *Nature Neuroscience*, vol. 22, no. 5, pp. 719–728, 2019.

[37] B. Yang, X. Dan, Y. Hou et al., “NAD+ supplementation prevents STING-induced senescence in ataxia telangiectasia by improving mitophagy,” *Aging Cell*, vol. 20, no. 4, article e13329, 2021.

[38] Y. H. Lee, J. Y. Park, H. Lee et al., “Targeting mitochondrial metabolism as a strategy to treat senescence,” *Cell*, vol. 10, no. 11, 2021.

[39] S. K. Ghosh–Choudhary, J. Liu, and T. Finkel, “The role of mitochondria in cellular senescence,” *The FASEB Journal*, vol. 35, no. 12, article e21991, 2021.

[40] J. Wang, X. Qin, H. Sun et al., “Nogo receptor impairs the clearance of fibril amyloid-β by microglia and accelerates Alzheimer’s-like disease progression,” *Aging Cell*, vol. 20, no. 12, article e13515, 2021.

[41] J. Cheng, Y. Dong, J. Ma et al., “Microglial Calhm2 regulates neuroinflammation and contributes to Alzheimer’s disease pathology,” *Science Advances*, vol. 7, no. 35, 2021.

[42] R. Y. Pan, J. Ma, X. X. Kong et al., “Sodium rutin ameliorates Alzheimer’s disease-like pathology by enhancing microglial amyloid-beta clearance,” *Science Advances*, vol. 5, no. 2, article eaau6328, 2019.

[43] S. Imai and L. Guarente, “NAD+ and sirtuins in aging and disease,” *Trends in Cell Biology*, vol. 24, no. 8, pp. 464–471, 2014.

[44] M. Ajami, H. Pazoki-Toroudi, H. Amani et al., “Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols,” *Neuroscience and Biobehavioral Reviews*, vol. 73, pp. 39–47, 2017.

[45] J. Lim, Y. Song, J. H. Jang et al., “Aspirin-inspired acetyl-donating HDACs inhibitors,” *Archives of Pharmacal Research*, vol. 41, no. 10, pp. 967–976, 2018.

[46] C. Patrano and C. Baigent, “Role of aspirin in primary prevention of cardiovascular disease,” *Nature Reviews. Cardiology*, vol. 16, no. 11, pp. 675–686, 2019.

[47] I. Raber, C. P. McCarthy, M. Vaduganathan et al., “The rise and fall of aspirin in the primary prevention of cardiovascular disease,” *Lancet*, vol. 393, no. 10186, pp. 2155–2167, 2019.

[48] P. Kambel, K. Selvarajan, C. Aluganti Narasimulu, M. Nandave, and S. Parthsarathy, “Aspirin may promote mitochondrial biogenesis via the production of hydrogen peroxide and the induction of Sirtuin1/PGC-1α genes,” *European Journal of Pharmacology*, vol. 699, no. 1-3, pp. 55–61, 2013.

[49] K. L. Tsai, P. H. Huang, C. L. Kao et al., “Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis,” *Biochemical Pharmacology*, vol. 88, no. 2, pp. 189–200, 2014.

[50] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics,” *Science*, vol. 297, no. 5580, pp. 353–356, 2002.

[51] G. S. Bloom, “Amyloid-β and tau,” *JAMA Neurology*, vol. 71, no. 4, pp. 505–508, 2014.

[52] H. Sarrus and M. T. Heneka, “Microglia in Alzheimer’s disease,” *The Journal of Clinical Investigation*, vol. 127, no. 9, pp. 3240–3249, 2017.

[53] D. V. Hansen, J. E. Hanson, and M. Sheng, “Microglia in Alzheimer’s disease,” *The Journal of Cell Biology*, vol. 217, no. 2, pp. 459–472, 2018.

[54] Y. Tang and W. Le, “Differential roles of M1 and M2 microglia in neurodegenerative diseases,” *Molecular Neurobiology*, vol. 53, no. 2, pp. 1181–1194, 2016.

[55] R. Orthuela, C. A. McPherson, and G. J. Harry, “Microglial M1/M2 polarization and metabolic states,” *British Journal of Pharmacology*, vol. 173, no. 4, pp. 649–665, 2016.

[56] K. Sinivasan, B. A. Friedman, A. Etxeberria et al., “Alzheimer’s patient microglia exhibit enhanced aging and unique transcriptional activation,” *Cell Reports*, vol. 31, no. 13, article 107843, 2020.

[57] N. Sun, R. J. Youle, and T. Finkel, “The mitochondrial basis of aging,” *Molecular Cell*, vol. 61, no. 5, pp. 654–666, 2016.

[58] J. Y. Jang, A. Blum, J. Liu, and T. Finkel, “The role of mitochondria in aging,” *The Journal of Clinical Investigation*, vol. 128, no. 9, pp. 3562–3570, 2018.

[59] E. F. Fang, Y. Hou, K. Palikaras et al., “Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease,” *Nature Neuroscience*, vol. 22, no. 3, pp. 401–412, 2019.

[60] S. Lautrup, G. Lou, Y. Aman, H. Nilsen, J. Tao, and E. F. Fang, “Microglial mitophagy mitigates neuroinflammation in Alzheimer’s disease,” *Neurochemistry International*, vol. 129, article 104469, 2019.

[61] S. Lautrup, D. A. Sinclair, M. P. Mattson, and E. F. Fang, “NAD+ in brain aging and neurodegenerative disorders,” *Cell Metabolism*, vol. 30, no. 4, pp. 630–655, 2019.

[62] Y. Kida and M. S. Goligorsky, “Sirtuins, cell senescence, and vascular aging,” *The Canadian Journal of Cardiology*, vol. 32, no. 5, pp. 634–641, 2016.

[63] W. Grabowska, E. Sikora, and A. Bielak-Zmijewska, “Sirtuins, a promising target in slowing down the ageing process,” *Biogerontology*, vol. 18, no. 4, pp. 447–476, 2017.

[64] H. C. Chang and L. Guarente, “SIRT1 and other sirtuins in metabolism,” *Trends in Endocrinology and Metabolism*, vol. 25, no. 3, pp. 138–145, 2014.
[65] C. Chen, M. Zhou, Y. Ge, and X. Wang, “SIRT1 and aging related signaling pathways,” *Mechanisms of Ageing and Development*, vol. 187, article 111215, 2020.

[66] J. W. Hwang, H. Yao, S. Caito, I. K. Sundar, and I. Rahman, “Redox regulation of SIRT1 in inflammation and cellular senescence,” *Free Radical Biology & Medicine*, vol. 61, pp. 95–110, 2013.

[67] B. A. Q. Gomes, J. P. B. Silva, C. F. R. Romeiro et al., “Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: role of SIRT1,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 8152373, 15 pages, 2018.

[68] S. Chandra, M. Jana, and K. Pahan, “Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer’s disease via PPARα,” *The Journal of Neuroscience*, vol. 38, no. 30, pp. 6682–6699, 2018.

[69] J. Ryan, E. Storey, A. M. Murray et al., “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline,” *Neurology*, vol. 95, no. 3, pp. e320–e331, 2020.